Ongoing blood loss and iron-deficiency anemia are common problems in patients on hemodialysis; therefore, nephrology clinicians are particularly concerned with their patients who are scheduled for surgery Surgery can cause significant blood and iron losses, thereby worsening their preexisting anemia. However, patients on hemodialysis can be effectively treated preoperatively by adjusting their continued doses of intravenous (i.v.) iron and recombinant human erythropoietin (EPO) therapy, based on expected blood and iron losses. This valuable strategy can help improve surgical and anemia outcomes as well as decrease EPO requirements and the need for transfusions. This article examines the use of IV iron and EPO therapy as preventive therapy for anemia in patients on hemodialysis prior to invasive surgical procedures, illustrated with an experience from a dialysis unit and patient case studies.

译文

:持续的失血和缺铁性贫血是血液透析患者的常见问题;因此,肾脏病临床医生特别关心计划进行手术的患者。手术可能会导致大量的血液和铁丢失,从而加剧他们先前的贫血。但是,可以根据预期的血液和铁损失,通过调整静脉注射铁和重组人促红细胞生成素(EPO)治疗的持续剂量,对接受血液透析的患者进行术前有效治疗。这种有价值的策略可以帮助改善手术和贫血结果,并降低EPO需求和输血需求。本文探讨了在进行侵入性外科手术之前,静脉铁剂和EPO疗法作为血液透析患者贫血的预防性疗法的用途,并结合透析部门和患者案例研究的经验进行了说明。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录